Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Don't Want to Miss
Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair & statins
Sunday, March 5, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News You Don't Want to Miss

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 

READ MORE >
ACC.23 Together with the World Congress of Cardiology
Share on Twitter Share on Facebook Share on Linkedin

Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins

Share on Twitter Share on Facebook Share on Linkedin
ACC.23 Together with the World Congress of Cardiology
The conference kicked off with three late-breaking studies that could have a huge impact on patient care going forward. 
READ MORE >

In Case You Missed It

Popular artificial sweetener associated with greater risk of heart attack, stroke

The new study, led by a team of Cleveland Clinic specialists, was published in Nature Medicine. 

READ MORE >
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
Share on Twitter Share on Facebook Share on Linkedin

Popular artificial sweetener associated with greater risk of heart attack, stroke

Share on Twitter Share on Facebook Share on Linkedin
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
The new study, led by a team of Cleveland Clinic specialists, was published in Nature Medicine. 
READ MORE >

Q&A: Tim Attebery on why private equity-backed management companies are investing in cardiology

The CEO of Cardiovascular Associates of America, and former CEO of the American College of Cardiology, shared his perspective on the rise of private equity investments in cardiology. 

READ MORE >
Tim Attebery, DSc, MBA, the CEO of Cardiovascular Associates of America and former CEO of the American College of Cardiology (ACC)
Share on Twitter Share on Facebook Share on Linkedin

Q&A: Tim Attebery on why private equity-backed management companies are investing in cardiology

Share on Twitter Share on Facebook Share on Linkedin
Tim Attebery, DSc, MBA, the CEO of Cardiovascular Associates of America and former CEO of the American College of Cardiology (ACC)
The CEO of Cardiovascular Associates of America, and former CEO of the American College of Cardiology, shared his perspective on the rise of private equity investments in cardiology. 
READ MORE >

In Other News

Walmart Health expanding with 28 locations in 2024

With the growth trajectory, Walmart Health will have more than 75 locations by the end of 2024.

READ MORE >
walmart health
Share on Twitter Share on Facebook Share on Linkedin

Walmart Health expanding with 28 locations in 2024

Share on Twitter Share on Facebook Share on Linkedin
walmart health
With the growth trajectory, Walmart Health will have more than 75 locations by the end of 2024.
READ MORE >

Eli Lilly caps insulin costs at $35 per month

The company announced price reductions of 70% for its most commonly prescribed insulins.

READ MORE >
diabetes
Share on Twitter Share on Facebook Share on Linkedin

Eli Lilly caps insulin costs at $35 per month

Share on Twitter Share on Facebook Share on Linkedin
diabetes
The company announced price reductions of 70% for its most commonly prescribed insulins.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

TAVR for moderate aortic stenosis | BP drug recalled | Stroke prevention device fails | New Medicare cuts | CCTA-guided PCI
A new way to think about the heart health of women | GLP-1 drugs vs. metformin | Cannabis use may increase risk of CVD, stroke
New Medicare payment cuts | Telemedicine vs. in-person cardiology visits | FDA confirms Class I recall | Startup raises $160M
FDA approves transcatheter treatment for PVL | CCTA-guided PCI | Real-world RDN outcomes | J&J launches new IVL catheter
CCTA vs. IVUS for PCI guidance: Carlos Collet reviews the data | The real-world benefits of RDN | New TAVR tech falls short
TAVR Highlights: New data on treating moderate AS | CMS may expand coverage again | Is surgical backup still necessary?
GLP-1 drugs vs. metformin | BP drug recalled | The health risks of cannabis use | Energy drinks linked to heart issues
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme